Since the overall safety data for GLP-1R agonists from previous clinical trials in diabetic patients are reassuring, a few side effects of GLP-1R agonists including gastrointestinal symptoms, injection-site reactions, and an increased heart rate can preclude use of GLP-1R agonists in some cases, and such use needs to be avoided in subjects with medullary thyroid tumor or history of acute pancreatitis [63]. The gene discussed is GLP1R; the disease is acute pancreatitis.